Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The share is getting closer to its long-term support in weekly data, at EUR 52.82, which offers good timing for buyers.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 52.53 support.
  • The group's high margin levels account for strong profits.
  • This company will be of major interest to investors in search of a high dividend stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The underlying tendency is negative on the weekly chart below the resistance at 71.43 EUR
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
BAYER AG-9.48%56 539
JOHNSON & JOHNSON10.10%348 981
PFIZER0.05%233 072
ROCHE HOLDING LTD.13.87%227 848
NOVARTIS21.31%220 893
MERCK AND COMPANY10.68%206 641
ELI LILLY AND COMPANY-0.20%113 364
ABBVIE-14.55%111 910
AMGEN-3.88%105 129
SANOFI2.67%103 743
ASTRAZENECA8.60%98 485
GLAXOSMITHKLINE5.71%97 904
NOVO NORDISK AS11.77%91 011
BRISTOL-MYERS SQUIBB COMPAN..-5.08%75 440
CELGENE CORPORATION54.33%66 725
TAKEDA PHARMACEUTICAL CO LT..4.36%51 782
More Results
Financials (€)
Sales 2019 46 540 M
EBIT 2019 8 175 M
Net income 2019 3 479 M
Debt 2019 37 729 M
Yield 2019 5,24%
P/E ratio 2019 14,45
P/E ratio 2020 11,76
EV / Sales 2019 1,91x
EV / Sales 2020 1,79x
Capitalization 51 122 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes